FINWIRES · TerminalLIVE
FINWIRES

CRIF: Taiwan's Exports Expected to Hit About $861 Billion in 2026

By

-- Taiwan's exports are projected to surge to as high as $860.6 billion in 2026, driven by strong AI-related demand, according to CRIF estimates released Tuesday.

The outlook comes after exports reached a record $195.74 billion in the first quarter, soaring 51.1% from the same period a year earlier, and far exceeding earlier government forecasts.

March shipments alone hit an all-time high of $80.18 billion, up 61.8% annually. This marks the first time monthly exports surpassed the $80 billion threshold.

Growth was mainly powered by electronics, with semiconductor-related components and ICT products posting exceptional gains, while traditional sectors such as textiles and metals continued to lag.

ICT and audiovisual exports more than doubled in the first quarter, while electronic components rose 42.7%, driven by high AI demand.

CRIF said that despite global uncertainties, including weaker global trade forecasts, Taiwan's export momentum is expected to remain resilient on continued technology sector strength.

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS